Latest / Stock Movers / Monte Paschi Falls, Aberdeen Rises, Argenx Plunges
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio. News. The Stock Movers Report.
- 0:10Speaker 1: Your roundup of companies making moves in the stock market.
- 0:13Speaker 1: Harnessing the power of Bloomberg data.
- 0:16Speaker 2: Let's take a look now at some stocks on the
- 0:18Speaker 2: move today in Europe. I'm Rachel Evans with Stephen Carroll,
- 0:20Speaker 2: and we're joined by Bloomberg's breaking news editor, Louise Moon. Louise,
- 0:23Speaker 2: thank you for being here. More moves today concerning Montedipaschi.
- 0:27Speaker 2: It never ends. What's the latest?
- 0:28Speaker 1: Exactly.
- 0:29Speaker 3: The latest in the long takeover drama with Italian banks. So,
- 0:34Speaker 3: the latest being that the second largest shareholder for Montedipaschi
- 0:38Speaker 3: has said that they oppose the CEO's plan to buy
- 0:41Speaker 3: two other banks, Banco BPM and Banco Generali. So, this
- 0:44Speaker 3: is the CEO's proposal essentially to try and fend off
- 0:48Speaker 3: a takeover approach from Entessa and stay independent. But the
- 0:53Speaker 3: second largest shareholder opposing that plan joins the largest shareholder
- 0:57Speaker 3: in those views. So, that takes resistance to the board
- 1:01Speaker 3: above 32%. So, it's a big setback for the CEO's plans.
- 1:05Speaker 3: And therefore, a step forward, presumably, for Enteza. It improved
- 1:09Speaker 3: its offer to take over Montefiaschi earlier this month. And
- 1:13Speaker 3: it made it conditional on investors rejecting that counterproposal by
- 1:17Speaker 3: the CEO. So, Montefiaschi shares fell this morning, unsurprisingly, as
- 1:22Speaker 3: much as about 6%. And But it will all come
- 1:25Speaker 3: to a head at the end of October. So, the
- 1:27Speaker 3: vote from shareholders is at the end of October. High stakes,
- 1:30Speaker 3: as I say, for the future of the bank and
- 1:32Speaker 3: also for the CEO. This would weaken, obviously, his mandate
- 1:36Speaker 3: as well. So, the latest and I'm sure we'll see
- 1:39Speaker 3: more before the end of October.
- 1:41Speaker 1: You very kindly included a Belgian stock for me this morning, Louise.
- 1:45Speaker 1: You've got ArgenX down over 18%. What's going on?
- 1:49Speaker 3: Yeah, it's the steepest drop in a few years since
- 1:51Speaker 3: December 2023. What they've done is they've ended a late-stage
- 1:54Speaker 3: trial of one of their best-selling medicines. So, that's for
- 1:57Speaker 3: a chronic autoimmune disorder. They ended that after a monitoring
- 2:01Speaker 3: panel said that the study was unlikely to succeed. And
- 2:04Speaker 3: this is quite a big setback. The peak sales potential,
- 2:07Speaker 3: if this has succeeded, could have been as high as
- 2:09Speaker 3: $ 4 billion. At the same time, they said that they're
- 2:12Speaker 3: going to take an experimental medicine for celiac disease into
- 2:16Speaker 3: advanced trials. But analysts are saying that if that were
- 2:19Speaker 3: to be successful, that doesn't outweigh the failure of this
- 2:23Speaker 3: other blockbuster drug. So, a big hit for them this morning,
- 2:26Speaker 3: as you say, their shares plunging.
- 2:29Speaker 2: And then Aberdeen, they've been cutting their stake in Standard Life.
- 2:32Speaker 2: How are investors reacting?
- 2:34Speaker 3: So, for Aberdeen, their shares rose about 2% in morning trading.
- 2:39Speaker 3: They sold about half their stake in Standard Life, as
- 2:41Speaker 3: you say. So, that's 52 million shares. So, that's about
- 2:44Speaker 3: a 5% stake. And they raised growth proceeds of about
- 2:47Speaker 3: £ 440 million. So, for Aberdeen Group, this is them simplifying.
- 2:51Speaker 3: They're trying to boost and focus on their wealth and
- 2:53Speaker 3: investment arms, strengthening their balance sheet for future growth. For
- 2:57Speaker 3: Standard Life, their shares fell as much as about 8%. So,
- 3:01Speaker 3: the most in 18 months. That's because those shares have
- 3:04Speaker 3: been sold at a discount, about 3.7% discount to the
- 3:07Speaker 3: closing price on Wednesday. So, two different moves in that
- 3:10Speaker 3: share price there. But as I say, for Aberdeen Group,
- 3:14Speaker 3: it's a move forward. in terms of their growth plans
- 3:17Speaker 3: and Citi analysts, for example, saying that this could then
- 3:19Speaker 3: result in more bolt-on M & A deals for them.
- 3:23Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 3:27Speaker 1: us throughout the day for the latest roundup of companies
- 3:30Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 3:34Speaker 1: listen to Bloomberg Radio live. Catch us on YouTube, Bloomberg.com,
- 3:39Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 3:42Speaker 1: Business app.